United Therapeutics Corporation UTHR shares are trading lower by $8.00 at $127.34 in Monday's session.
Investors are exiting the issue following the announcement that the U.S. launch of RemoSynch will be delayed due to regulatory delays.
The stock, which has been out of favor with the Street since it peaked in February at $169.89, made its all-time in June 2015 at $190.13.
After a much lower open, it immediately bottomed at $121.23 and began to move higher. So far, the ensuing rally has come up shy of the lower-end of Friday's range ($133.07), as $129.35 stands as the high for the session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
